Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
11.11
0.00 (0.00%)
Aug 1, 2025, 4:00 PM - Market closed

Company Description

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.

The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy.

The company is also developing Celiprolol, a prodrug product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome.

In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder.

The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA.

The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023.

Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Zevra Therapeutics, Inc.
Zevra Therapeutics logo
CountryUnited States
Founded2006
IPO DateApr 16, 2015
IndustryBiotechnology
SectorHealthcare
Employees59
CEONeil McFarlane

Contact Details

Address:
1180 Celebration Boulevard, Suite 103
Celebration, Florida 34747
United States
Phone321 939 3416
Websitezevra.com

Stock Details

Ticker SymbolZVRA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001434647
ISIN NumberUS4884452065
Employer ID20-5894398
SIC Code2834

Key Executives

NamePosition
Neil F. McFarlanePresident, Chief Executive Officer and Director
R. LaDuane Clifton CPAChief Financial Officer and Treasurer
Dr. Adrian Quartel FFPM, M.D.Chief Medical Officer
Nichol L. OchsnerVice President of Investor Relations and Corporate Communications
Rahsaan W. Thompson J.D.Chief Legal Officer, Secretary and Compliance Officer
Alison PetersChief People Officer
Dr. Christopher M. Lauderback Ph.D.Senior Vice President of Manufacturing
Joshua M. Schafer M.B.A.Chief Commercial Officer
Gerald J. OrehostkySenior Vice President of Regulatory Affairs and Quality
Tanya HaydenSenior Vice President and Chief of Staff

Latest SEC Filings

DateTypeTitle
Jun 26, 2025144Filing
May 29, 20258-KCurrent Report
May 21, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
May 13, 202510-QQuarterly Report
May 13, 20258-KCurrent Report
May 8, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2025DEFC14AFiling
Apr 24, 2025PRRN14AFiling
Apr 23, 2025DFAN14AFiling
Apr 21, 2025DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) material